Search research articles
Contact Us
Filters
Showing results (101-110 of 118) with videos related to
Page
of 12
Sort By:
Gynecologic Oncology
|
June 8, 2026
Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004
Xiaodan Tang, Helen Huang, John D Peipert, et al.
Journal of the National Cancer Institute
|
April 5, 2017
Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence
Theodore M Brasky, Ashley S Felix, David E Cohn, et al.
British Journal of Cancer
|
January 10, 2024
Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer
Chae Young Han, Jacob S Bedia, Wei-Lei Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial
Joyce F Liu, Mark F Brady, Ursula A Matulonis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
Jung-Min Lee, Mark F Brady, Austin Miller, et al.
Biorxiv : the Preprint Server for Biology
|
May 18, 2026
IL1β/IL1R1/IRAK4 Drives Inflammatory Ovarian Cancer Seeding at the inflamed sites and Is Reversed by an IRAK4 inhibitor UR241-2
John P Miller, Kyu Kwang Kim, Cameron Wa Snyder, et al.
Gynecologic Oncology
|
May 13, 2022
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
Roisin E O'Cearbhaill, Jose-Alejandro Pérez-Fidalgo, Bradley J Monk, et al.
Biorxiv : the Preprint Server for Biology
|
June 22, 2026
Reconstruction of septin higher-order nano-size structures in ovarian cancer cells uncover susceptibility to the septin-targeting small molecule UR214-9
Negar Khazan, Cameron Wa Snyder, Nicole Dawney, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 6, 2026
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial
Christian Marth, Richard G Moore, Mariusz Bidziński, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2024
Normal Risk Ovarian Screening Study: 21-Year Update
Chae Young Han, Karen H Lu, Gwen Corrigan, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 118) with videos related to
Sort By:
Page
of 12
Gynecologic Oncology
|
June 8, 2026
Psychometric evaluation of the NFOSI-18 disease related symptoms - Physical, NFOSI-18 Total, and FACT GP5 in the recurrent ovarian cancer phase III study GY004
Xiaodan Tang, Helen Huang, John D Peipert, et al.
Journal of the National Cancer Institute
|
April 5, 2017
Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence
Theodore M Brasky, Ashley S Felix, David E Cohn, et al.
British Journal of Cancer
|
January 10, 2024
Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer
Chae Young Han, Jacob S Bedia, Wei-Lei Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial
Joyce F Liu, Mark F Brady, Ursula A Matulonis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
Jung-Min Lee, Mark F Brady, Austin Miller, et al.
Biorxiv : the Preprint Server for Biology
|
May 18, 2026
IL1β/IL1R1/IRAK4 Drives Inflammatory Ovarian Cancer Seeding at the inflamed sites and Is Reversed by an IRAK4 inhibitor UR241-2
John P Miller, Kyu Kwang Kim, Cameron Wa Snyder, et al.
Gynecologic Oncology
|
May 13, 2022
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
Roisin E O'Cearbhaill, Jose-Alejandro Pérez-Fidalgo, Bradley J Monk, et al.
Biorxiv : the Preprint Server for Biology
|
June 22, 2026
Reconstruction of septin higher-order nano-size structures in ovarian cancer cells uncover susceptibility to the septin-targeting small molecule UR214-9
Negar Khazan, Cameron Wa Snyder, Nicole Dawney, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 6, 2026
First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial
Christian Marth, Richard G Moore, Mariusz Bidziński, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 9, 2024
Normal Risk Ovarian Screening Study: 21-Year Update
Chae Young Han, Karen H Lu, Gwen Corrigan, et al.
Page
of 12